Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00203970 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Jan 2024 to Jan 2027v14
  2. Completion date: Jan 2021 to Jan 2024v13
  3. Completion date: Jan 2019 to Jan 2021v12
  4. Completion date: Jan 2017 to Jan 2019v11
  5. Completion date: Jan 2014 to Jan 2017v10
Show 8 earlier versionsHide 8 earlier versions
  1. Completion date: Jan 2012 to Jan 2014v9
  2. Study Status, Outcome Measuresv8
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 800 to confirmed 645 · Primary completion date: Mar 2001 · Completion date: Jan 2012 · 2 morev7 Show 5 more changesShow less
    • Enrollment target: estimated 800 to confirmed 645
    • Primary completion date: Mar 2001
    • Completion date: Jan 2012
    • Study description expanded, about 137 words
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  4. 5 versions Re-verified since Mar 10, 2006, no change to tracked fieldsv2-v6
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks. We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the social network of general internal medicine interns, residents, and attendings at the University of Chicago Hospital. In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with Coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. A DVT critical pathway was established at the U of C in 1998, and LMWH was used off-label for that purpose beginning in 1997. However, it is unclear how quickly the use of LMWH was adopted by the physicians on the general medicine services, or whether there exists a pattern for this adoption.
Trial Details
NCT Number NCT00203970
Lead Sponsor University of Chicago
Conditions Thrombosis
Enrollment 645 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov